welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Efficacy and Safety of Eflornithine (CPP-1X)/Sulindac Combination Therapy Versus Each as Monotherapy in Patients wit...BACKGROUND: Molecular studies suggest i...
-
Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)Hereditary forms of colorectal cancer ac...
-
Familial Adenomatous Polyposis (FAP) – Inheritedhttps://my.clevelandclinic.org/ccf/media...
-
Curcumin in Treating Patients With Familial Adenomatous PolyposisThis clinical trial studies curcumin in ...
-
Desmoid Tumour in Familial Adenomatous Polyposis Patients: Responses to TreatmentsNo guidelines for desmoid tumors (DT) ma...
-
Clinical Management of Adenomatous Polyposis in Patients with Hereditary Non-Polyposis Colorectal Cancer and Familia...OBJECTIVE : To investigate the validity ...